KPV — Research Overview
Chemical Name: Lysine-Proline-Valine Also Known As: KPV, α-MSH(11-13), Lys-Pro-Val, alpha-MSH C-terminal tripeptide One-Letter Abbreviation: K-P-V (from the single-letter amino acid codes for Lysine, Proline, and Valine) Source: Endogenous fragment — KPV constitutes amino acids 11 through 13 at the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH), the tridecapeptide SYSMEHFRWGKPV Structure: Tripeptide (3 amino acids) — the minimal bioactive C-terminal sequence of α-MSH retaining the parent molecule’s anti-inflammatory activity Molecular Weight: Approximately 329.4 daltons Relationship to α-MSH: Alpha-melanocyte-stimulating hormone is a 13-amino acid neuropeptide derived from proopiomelanocortin (POMC) by post-translational processing. The active core for melanocortin receptor binding and pigmentation is located in the central pharmacophore sequence (His-Phe-Arg-Trp, positions 6-9). The C-terminal tripeptide KPV (positions 11-13) carries the anti-inflammatory and antimicrobial activity of the parent molecule through a mechanism that is entirely distinct from and independent of melanocortin receptor activation. Key Research Insight: Most of the anti-inflammatory activities of full-length α-MSH can be attributed to its C-terminal tripeptide KPV. KPV can exert similar or even more pronounced anti-inflammatory activity than the full-length parent molecule while lacking melanocortin receptor-mediated effects including melanogenesis (skin pigmentation). Category: Endogenous anti-inflammatory tripeptide / α-MSH C-terminal fragment / NF-kB pathway inhibitor / PepT1 substrate / gut and skin inflammatory disease research tool
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is KPV?
KPV is a naturally occurring endogenous tripeptide comprising the three C-terminal amino acids of alpha-melanocyte-stimulating hormone — one of the most extensively studied anti-inflammatory neuropeptides in the melanocortin family. The discovery that the three amino acid C-terminal fragment of α-MSH retains significant or even enhanced anti-inflammatory activity while losing the melanocortin receptor-mediated effects that limit the clinical utility of the full-length molecule represented a paradigm shift in melanocortin anti-inflammatory research.
Full-length α-MSH has been well established as a potent anti-inflammatory agent with demonstrated efficacy in animal models of fever, contact dermatitis, cutaneous vasculitis, asthma, inflammatory bowel disease, rheumatoid arthritis, ocular inflammation, and brain inflammation. However, its clinical development as a therapeutic agent has been complicated by its broad biological activity profile — particularly its melanocortin receptor-mediated capacity to induce skin pigmentation, influence appetite, and affect sexual function. These additional effects arise from α-MSH’s central pharmacophore (the His-Phe-Arg-Trp sequence that binds melanocortin receptors with high affinity) which is absent from the KPV fragment.
KPV retains the anti-inflammatory potency of the full-length molecule through a mechanistic pathway that is independent of melanocortin receptors — direct intracellular NF-kB inhibition, operating via transport into cells through the PepT1 di/tripeptide transporter. This mechanism simultaneously explains KPV’s effectiveness at nanomolar concentrations, its oral bioavailability potential (unusual for therapeutic peptides), and its lack of melanocortin receptor-mediated side effects.
The oral bioavailability angle deserves emphasis as an unusual property in the peptide research landscape. Most therapeutic peptides require parenteral administration because they are degraded in the gastrointestinal tract before reaching systemic circulation. KPV’s small size and its identity as a substrate for the PepT1 transporter — which actively transports di- and tripeptides across the intestinal epithelium — provides a biological uptake mechanism not available to larger peptides. This is particularly relevant for gut inflammatory conditions such as IBD, where colonic PepT1 expression is upregulated during active inflammation, potentially increasing KPV uptake precisely at the sites of greatest inflammatory activity.
The Mechanistic Discovery — Why KPV Is Not Just a Smaller Version of α-MSH
The relationship between KPV and α-MSH involves a critical mechanistic distinction that is central to KPV’s research identity. When KPV was first identified as carrying the anti-inflammatory activity of α-MSH, the default assumption was that it must operate through the same melanocortin receptors as the parent molecule — MC1R being the primary anti-inflammatory melanocortin receptor expressed on immune cells and keratinocytes.
The 2008 landmark study by Dalmasso et al. in Gastroenterology directly investigated this assumption and overturned it. Using human intestinal epithelial cells (Caco2-BBE), the researchers found that KPV did not increase intracellular cAMP — the second messenger induced by melanocortin receptor activation — even though cells expressed MC3R and MC5R. KPV did not compete with α-MSH for receptor binding. And crucially, KPV retained full anti-inflammatory activity in mice with nonfunctional MC1R (MC1Re/e mice) — demonstrating that its effects are genuinely melanocortin receptor-independent.
What the study established instead was that KPV enters intestinal epithelial cells through PepT1 (the human oligopeptide transporter SLC15A1), accumulates intracellularly, and directly inhibits NF-kB activation from inside the cell. This PepT1-mediated intracellular mechanism explains both the potency of KPV at very low concentrations and its selective activity in inflamed tissue, where PepT1 expression is upregulated.
This mechanistic discovery has practical implications: KPV’s anti-inflammatory effects in gut tissue are not dependent on melanocortin receptor expression or function, meaning it operates through a pharmacologically distinct pathway from α-MSH and its analogs. This also means KPV lacks the melanocortin receptor-mediated effects (pigmentation, appetite modulation, sexual effects) that have limited α-MSH’s clinical development — making it a pharmacologically cleaner anti-inflammatory tool.
Mechanism of Action
Intracellular NF-kB inhibition: KPV’s primary documented mechanism of anti-inflammatory action is inhibition of NF-kB nuclear translocation. NF-kB is the master transcription factor that controls expression of a broad range of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-8), chemokines, adhesion molecules, and inducible inflammatory enzymes including cyclooxygenase-2 and inducible nitric oxide synthase. Under resting conditions, NF-kB is sequestered in the cytoplasm by its inhibitory binding partner IkB-alpha. Pro-inflammatory stimuli (cytokines, LPS, oxidative stress) activate the IKK complex, which phosphorylates and targets IkB-alpha for proteasomal degradation, releasing NF-kB to translocate into the nucleus and activate inflammatory gene expression. KPV stabilizes IkB-alpha protein levels in cells exposed to pro-inflammatory stimuli (IL-1beta, TNF-alpha), preventing the IkB-alpha degradation that would release NF-kB, thereby blocking the entire downstream inflammatory gene expression cascade. Importantly, KPV does not suppress baseline (uninduced) NF-kB activity — it reduces excessive or pathological NF-kB activation without blunting physiological inflammatory signaling required for normal immune function.
PepT1-mediated cellular entry: KPV is actively transported into intestinal epithelial cells and immune cells via PepT1 (human intestinal peptide transporter 1, SLC15A1), a proton-coupled transporter that normally mediates uptake of dietary di- and tripeptides. PepT1 is constitutively expressed in the small intestine and is upregulated in the colon during inflammatory bowel disease — creating a self-amplifying uptake mechanism in inflamed gut tissue. This transporter-mediated cellular entry explains KPV’s ability to act intracellularly at the level of NF-kB, and also explains its unusual potential for oral bioavailability.
MAPK pathway modulation: In addition to NF-kB inhibition, KPV attenuates activation of key MAPK (mitogen-activated protein kinase) signaling cascades including ERK1/2 and p38 MAPK — pathways that contribute to inflammatory cytokine production and cellular stress responses. This MAPK modulation has been documented in keratinocyte research examining KPV’s protection against oxidative damage from environmental particulate matter.
Pro-inflammatory cytokine suppression: As downstream consequences of NF-kB and MAPK inhibition, KPV significantly reduces production of TNF-alpha, IL-1beta, IL-6, IL-8, and other pro-inflammatory mediators across multiple cell types including intestinal epithelial cells, T lymphocytes, macrophages, keratinocytes, and bronchial epithelial cells.
Antimicrobial activity: KPV and full-length α-MSH have been demonstrated to exert direct antimicrobial effects against Staphylococcus aureus and Candida albicans at physiological (picomolar) concentrations. This antimicrobial activity is mechanistically separate from the anti-inflammatory NF-kB pathway and is believed to involve cAMP-mediated mechanisms or direct membrane interaction. Importantly, KPV’s antimicrobial effect does not impair neutrophil killing of pathogens — unlike conventional anti-inflammatory agents, KPV appears to combine direct pathogen suppression with inflammatory modulation while preserving the body’s own antimicrobial immune capacity.
IL-1 receptor interaction: A secondary proposed mechanism involves KPV’s potential to interact with the IL-1 receptor type I (IL-1RI) as a partial antagonist. Structural analysis suggests that during degradation of full-length IL-1beta, the C-terminal loop containing a KPV-like sequence (positions 193-195) is exposed and may interact with IL-1RI to competitively reduce IL-1beta-mediated inflammatory signaling. This mechanism, if confirmed, would provide a second intracellular or receptor-level pathway for anti-inflammatory activity independent of PepT1 transport.
Published Research
Study 1 — Foundational Mechanism: Anti-Inflammatory Activity of the α-MSH C-Terminal Fragment
Authors: Catania A, Rajora N, Bhatt S, Ceriani V, Lipton JM (University of Texas) Year: 1996 / 2000 (systematic characterization) Journal: FASEB Journal and subsequent publications Referenced via published literature (PMID series from Catania/Lipton group)
The systematic investigation by Catania, Lipton, and colleagues established through a series of publications that the three C-terminal amino acids of α-MSH (KPV) constitute the minimal sequence responsible for the parent molecule’s anti-inflammatory activity, and that this activity is not dependent on the central pharmacophore required for melanocortin receptor binding.
Truncation studies of α-MSH demonstrated that deletion of the N-terminal and central portions of the molecule while retaining the C-terminal KPV sequence preserved significant anti-inflammatory potency, while N-terminally extended fragments lacking the KPV sequence lost anti-inflammatory activity.
The COOH-terminal fragment of α-MSH produced anti-inflammatory effects in vivo comparable to the full-length tridecapeptide, demonstrating that the 3-amino acid fragment was sufficient to carry the parent molecule’s anti-inflammatory biological information.
This finding was described as paradigm-shifting: it demonstrated for the first time that anti-inflammatory activity and melanocortin receptor binding activity are carried by different domains of α-MSH — separating the pigmentation, appetite, and sexual effects of the parent molecule from its anti-inflammatory utility.
Antimicrobial characterization published in the Journal of Leukocyte Biology (2000) documented that α-MSH and KPV inhibit Staphylococcus aureus colony formation (including reversing urokinase-enhanced colony formation) and reduce Candida albicans viability and germ tube formation at physiological picomolar concentrations — establishing the combined anti-inflammatory and antimicrobial profile.
Study 2 — IBD Animal Models: KPV Demonstrates Anti-Inflammatory Efficacy in Two Murine Colitis Models
Authors: Kannengiesser K, Maaser C, Heidemann J et al. (University of Münster) Year: 2008 Journal: Inflammatory Bowel Diseases Full text: https://academic.oup.com/ibdjournal/article-abstract/14/3/324/4653598
This study directly evaluated the therapeutic potential of KPV in two well-characterized murine models of inflammatory bowel disease — the DSS (dextran sodium sulfate) colitis model and the CD45RBhi T-cell transfer colitis model — establishing KPV’s anti-inflammatory efficacy across distinct mechanistic models of intestinal inflammation.
KPV demonstrated significant anti-inflammatory effects in both the DSS colitis model and the T-cell transfer colitis model, as measured by weight loss, histological changes in the colon, and myeloperoxidase (MPO) activity (an established biomarker of intestinal neutrophil infiltration).
A critical mechanistic experiment was included: animals expressing a nonfunctional MC1R (MC1Re/e mice) were treated with DSS-induced colitis and received KPV. The anti-inflammatory effects of KPV were retained in these MC1R-deficient animals — directly establishing that KPV’s colitis-protective effects are at least partially independent of MC1R signaling, challenging the assumption that KPV must operate through melanocortin receptors.
The authors concluded that KPV is an interesting therapeutic option for the treatment of IBD, with a mechanism of action that does not require intact melanocortin receptor signaling — positioning it as a pharmacologically distinct candidate from α-MSH analogs that depend on MC1R activation.
Study 3 — Landmark Mechanism: PepT1-Mediated KPV Transport Reduces Intestinal Inflammation
Authors: Dalmasso G, Charrier-Hisamuddin L, Thu Nguyen HT, et al. Year: 2008 Journal: Gastroenterology PMID referenced via: https://www.gastrojournal.org/article/S0016-5085(07)01852-5/abstract Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/
This landmark Gastroenterology paper established the mechanism by which KPV exerts its anti-inflammatory effects in the gut — directly overturning the melanocortin receptor hypothesis and establishing PepT1-mediated intracellular NF-kB inhibition as the operative pathway.
Human intestinal epithelial cells (Caco2-BBE and HT29-Cl.19A) and human T cells (Jurkat) were stimulated with pro-inflammatory cytokines in the presence or absence of KPV. NF-kB activity was assessed using a luciferase reporter system, Western blot for IkB-alpha, RT-PCR, and ELISA for cytokine production.
KPV inhibited NF-kB activation in both intestinal epithelial cells and T cells stimulated with IL-1beta and TNF-alpha respectively — demonstrating broad anti-inflammatory activity across the two major cell types in contact at the gut mucosal interface.
Mechanistic investigation confirmed that KPV does not act through melanocortin receptors: cAMP levels were not increased by KPV treatment, and KPV did not compete with α-MSH for receptor binding. The anti-inflammatory activity of KPV was retained in MC1R-nonfunctional mice, confirming receptor-independent action.
KPV was confirmed as a substrate for PepT1 through radiolabeled uptake experiments — KPV actively transported into cells via PepT1, explaining both its intracellular site of action and its oral uptake potential via the constitutively expressed small intestinal PepT1 and the colitis-upregulated colonic PepT1.
In two in vivo mouse colitis models (DSS-induced and TNBS-induced), orally delivered KPV significantly decreased the severity of colitis, demonstrating that the PepT1-mediated mechanism is operational in vivo following oral administration.
The authors concluded that the anti-inflammatory effect of KPV is not MCR-mediated but PepT1-mediated, with KPV accumulating intracellularly and inactivating inflammatory pathways after transport — establishing the mechanistic foundation for all subsequent KPV research.
Study 4 — Antimicrobial and Anti-Inflammatory Dual Activity
Authors: Brzoska T et al. (University of Münster) Year: 2008 Journal: Published in Peptides and related literature Referenced via PMC2095288
This study characterized the antimicrobial activity of the α-MSH C-terminal peptide KPV alongside its anti-inflammatory properties, establishing KPV’s dual pharmacological profile — an unusual combination of direct antimicrobial activity and anti-inflammatory action without immune suppression.
KPV demonstrated antimicrobial effects against Staphylococcus aureus and Candida albicans at concentrations including the physiological picomolar range — establishing that the antimicrobial activity is not a pharmacological artifact of supraphysiological dosing but is potentially relevant at endogenous concentrations.
A key finding distinguished KPV from conventional anti-inflammatory agents: KPV’s anti-inflammatory effects did not reduce neutrophil killing activity against pathogens. This preservation of innate immune pathogen-killing capacity alongside reduced inflammatory signaling represents a favorable profile compared to immunosuppressive anti-inflammatory drugs that weaken host defense.
The candidacidal activity of α-MSH and KPV was further characterized, with the finding that inserting a Cys-Cys linker between two KPV units could enhance the antifungal potency — suggesting structural optimization potential for antimicrobial applications.
The review authors concluded that the combined anti-inflammatory and antimicrobial effects of α-MSH-related tripeptides, particularly KPV, make them interesting candidates for the treatment of immune-mediated inflammatory skin and bowel diseases, allergic asthma, and arthritis — specifically noting that the combined anti-inflammatory and antimicrobial profile (not achievable with conventional immunosuppressants) represents a meaningful pharmacological advantage in inflammatory disease contexts where infection risk is a concern.
Study 5 — Skin and Keratinocyte Protection: KPV Against Oxidative Stress and Inflammation
Authors: Jeon et al. Year: 2025 Journal: ScienceDirect Full text: https://www.sciencedirect.com/science/article/abs/pii/S004081662500117X
This recent study examined KPV’s protective effects against environmental particulate matter (PM10)-induced oxidative stress, inflammation, and apoptosis in human HaCaT keratinocytes and a three-dimensional skin model — extending KPV research from gut inflammation into a skin biology context and characterizing the MAPK pathway modulation in addition to NF-kB inhibition.
PM10 exposure markedly suppressed keratinocyte proliferation through cytotoxic effects and induced a pro-inflammatory response by increasing IL-1beta secretion. KPV at 50 micrograms/mL restored cell viability and reduced IL-1beta secretion in PM10-exposed cells.
KPV inhibited ROS production induced by PM10, which in turn blocked activation of ERK and p38 MAPK — demonstrating that KPV’s anti-inflammatory effects in keratinocytes operate through redox-sensitive MAPK pathways in addition to the NF-kB pathway characterized in gut epithelial cells.
KPV decreased expression of apoptosis-related proteins including Bax, cleaved caspase-3, and IL-1beta through suppression of NF-kB, and blocked ROS-mediated caspase-1 activation, reducing the inflammatory cell death pathway (pyroptosis) in PM10-exposed keratinocytes.
In a three-dimensional skin model, KPV treatment effectively attenuated the inflammatory cell death induced by PM10, confirming the in vitro cell line findings in a more physiologically relevant tissue context.
The authors concluded that KPV protects keratinocytes by mitigating PM10-induced pyroptosis and holds potential as a therapeutic agent for preventing environmental pollutant-related skin damage — extending KPV’s documented research applications into dermatological and environmental health contexts.
Study 6 — Wound Healing and Tripeptide Review in Tissue Repair
Authors: Comprehensive review published 2025 Journal: International Journal of Medical Sciences (PMC) Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12595317/
This 2025 systematic review covering tripeptide research in wound healing specifically characterized KPV’s contributions alongside GHK-Cu and other bioactive tripeptides, synthesizing the evidence for KPV’s role in tissue repair contexts.
KPV-loaded hydrogel formulations reduce inflammation, promote tissue regeneration, and demonstrate antibacterial activity against MRSA (methicillin-resistant Staphylococcus aureus) — an important pathogen in chronic wound contexts where conventional antibiotics are often ineffective.
KPV has been studied in animal corneal wound healing models: topical KPV application four times daily produced significantly smaller wound areas compared to controls after four days of treatment, with corneal epithelial cell cultures demonstrating direct stimulation by KPV exposure — suggesting both anti-inflammatory and pro-regenerative contributions to wound repair.
The anti-inflammatory and antimicrobial properties of KPV make it a valuable research candidate for both acute and chronic wound management, particularly in contexts where both infection control and inflammation resolution are required simultaneously.
The review highlighted KPV’s mechanistic position alongside GHK-Cu (the other endogenous anti-inflammatory tripeptide in this research catalog) — two distinct endogenous tripeptides with complementary wound healing pharmacology through entirely different mechanisms (KPV through NF-kB/PepT1, GHK-Cu through copper-mediated tissue remodeling and angiogenesis).
KPV in Research Context: Key Themes
The KPV research literature has several consistent and notable themes that are worth understanding for research protocol design.
Oral bioavailability through PepT1: KPV’s identity as a PepT1 substrate makes it one of the few therapeutic peptides with demonstrated oral absorption potential through an active transport mechanism rather than passive diffusion. The upregulation of PepT1 in inflamed colonic tissue during IBD creates a disease-specific uptake enhancement — inflamed gut tissue is more capable of absorbing KPV than healthy gut tissue. This represents a pharmacologically elegant self-targeting mechanism: KPV absorption is amplified at the sites of greatest therapeutic need.
Anti-inflammatory without immunosuppression: KPV’s NF-kB inhibitory effects are modulatory rather than ablative — published data consistently shows that KPV reduces excessive or pathological NF-kB activation while not fully suppressing baseline physiological NF-kB activity. This partial suppression profile is mechanistically distinct from complete NF-kB blockers or corticosteroids, which produce broad immunosuppression.
Combined anti-inflammatory and antimicrobial: The unusual combination of direct antimicrobial activity against major pathogens (Staphylococcus aureus, Candida albicans) alongside anti-inflammatory NF-kB inhibition — without impairing neutrophil pathogen-killing — represents a favorable pharmacological profile for inflammatory disease contexts where concurrent infection is a risk or concern.
Skin and gut as primary research domains: KPV research has concentrated in two tissue contexts where its parent molecule α-MSH is most relevant physiologically — the gut epithelium and the skin. Both tissues are sites of chronic inflammatory diseases (IBD, colitis vs dermatitis, psoriasis, wound healing) where current treatments have significant limitations. KPV’s small size and topical/oral delivery potential are particularly well-suited to these tissue targets.
Current Research Status
KPV is not FDA-approved for any therapeutic indication. All published evidence is preclinical — in vitro cell culture studies and in vivo animal models. No human clinical trials of KPV have been completed and published. Research continues actively in IBD, colitis, skin inflammatory diseases, wound healing, and antimicrobial applications. Novel delivery formulations including KPV-loaded hydrogels, nanoparticles, and mucoadhesive delivery systems are active areas of investigation to optimize KPV bioavailability and tissue targeting.
Reconstitution Note
KPV is a synthetic tripeptide. Bacteriostatic water is the standard reconstitution solvent. KPV dissolves readily in aqueous solution. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the KPV product page: https://roguecompounds.com/product/kpv/